VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
WSTWest Pharmaceutical Services, Inc.
$329.71$23.8B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksWSTEarnings History

WST logoWest Pharmaceutical Services, Inc. (WST) Earnings History

Steady Earner

37 years of earnings data (1989–2025) · Positive but moderate multi-year EPS trajectory

TTM Net Income
$543M
● Profitable
TTM EPS (Diluted)
$7.50
Per share, diluted
YoY EPS Growth
+1.6%
Solid
Net Margin
16.1%
After-tax profitability
EPS Growth Rate (CAGR)
1Y+1.6%
3Y-4.2%
5Y+8.3%
10Y+18.0%
Operating Margin20.1%
Gross Margin35.9%
Return on Equity16.9%
Return on Assets12.5%
Record Annual Net Income$662MFY2021
Record Quarterly EPS$2.49Q2 2022
Consecutive Profitable Years24years
Q1 2026
Net Income$139M
EPS (Diluted)$1.92
YoY Growth+1.6%Solid
QoQ Growth+5.1%Solid

Loading earnings history...

West Pharmaceutical Services, Inc. (WST) Earnings Overview

As of June 23, 2026, West Pharmaceutical Services, Inc. (WST) reported trailing twelve-month net income of $543M, reflecting +1.6% year-over-year growth. The company earned $7.50 per diluted share over the past four quarters, with a net profit margin of 16.1%.

Looking at the long-term picture, WST's 5-year EPS compound annual growth rate (CAGR) stands at +8.3%, showing solid earnings momentum. The company achieved its highest annual net income of $662M in fiscal 2021.

West Pharmaceutical Services, Inc. maintains industry-leading profitability with a gross margin of 35.9%, operating margin of 20.1%, and net margin of 16.1%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →

Compared to peers including ATR ($387M net income, 10.4% margin), GTLS (-$26M net income, 1.0% margin), AVTR (-$551M net income, -8.1% margin), WST has outperformed on profitability metrics. Compare WST vs ATR →

WST Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
WST logoWSTCurrent
$543M$7.5016.1%16.9%+1.6%—
ATR logoATR
$387M$5.9610.4%15.1%+6.3%
GTLS logoGTLS
-$26M$-0.571.0%1.3%-92.0%
AVTR logoAVTR
-$551M$-0.81-8.1%-9.2%-175.0%
AMCR logoAMCR
$678M$1.463.4%6.5%-36.8%
SEE logoSEE
$506M$3.439.4%54.3%+89.5%
Best in group
Lowest in group

WST Historical Earnings Data (1989–2025)

37 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$494M+0.2%$617M$6.8016.1%20.1%
2024$493M-17.0%$595M$6.6917.0%20.6%
2023$593M+1.3%$711M$7.8820.1%24.1%
2022$586M-11.5%$764M$7.7320.3%26.5%
2021$662M+91.2%$759M$8.6723.4%26.8%
2020$346M+43.2%$419M$4.5716.1%19.5%
2019$242M+16.8%$297M$3.2113.1%16.1%
2018$207M+37.3%$255M$2.7412.0%14.8%
2017$151M+4.9%$230M$1.999.4%14.4%
2016$144M+50.2%$216M$1.919.5%14.3%
2015$96M-24.8%$126M$1.306.8%9.0%
2014$127M+13.2%$182M$1.758.9%12.8%
2013$112M+39.2%$157M$1.578.2%11.5%
2012$81M+6.9%$137M$1.156.4%10.8%
2011$76M+15.6%$116M$1.086.3%9.7%
2010$65M-10.1%$106M$0.955.9%9.6%
2009$73M-15.6%$106M$1.066.9%10.0%
2008$86M+21.6%$125M$1.258.2%11.9%
2007$71M+5.4%$113M$1.026.9%11.1%
2006$67M+47.1%$106M$1.007.3%11.6%
2005$46M+135.1%$73M$0.716.5%10.5%
2004$19M-39.2%$64M$0.563.6%11.8%
2003$32M+73.4%$55M$0.756.5%11.1%
2002$18M+453.8%$27M$0.334.4%6.4%
2001-$5M-425.0%$41M$-0.09-1.3%10.4%
2000$2M-95.9%$36M$0.030.4%8.3%
1999$39M+477.6%$66M$0.648.2%14.2%
1998$7M-84.9%$65M$0.101.5%14.4%
1997$44M+170.7%$62M$0.679.8%13.7%
1996$16M-42.9%$53M$0.253.6%11.6%
1995$29M+5.1%$48M$0.437.0%11.7%
1994$27M+16.2%$47M$0.437.5%12.9%
1993$24M+19.3%$41M$0.376.7%11.8%
1992$20M+331.8%$40M$0.315.8%11.7%
1991-$9M-297.7%-$1M$-0.14-2.6%-0.4%
1990$4M-79.2%$21M$0.071.3%6.6%
1989$21M-$36M$0.326.7%11.7%

Download Data

Export WST earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into WST consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

37+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

WST — Frequently Asked Questions

Quick answers to the most common questions about buying WST stock.

What is WST earnings per share (EPS)?

WST trailing twelve-month (TTM) diluted EPS is $7.50, reflecting +1.6% year-over-year growth. The 5-year EPS CAGR is +8.3%. Complete EPS history from 1989 to 2025 is available in the table on this page.

What is West Pharmaceutical Services, Inc.'s net income?

West Pharmaceutical Services, Inc. (WST) trailing twelve-month net income is $543M as of 2025. Earnings grew +1.6% year-over-year. West Pharmaceutical Services, Inc. has been profitable for 24 consecutive years.

Is WST profitable?

Yes, WST is profitable with a TTM net income of $543M and a net profit margin of +16.1%. West Pharmaceutical Services, Inc. has generated profits for 24 consecutive years.

What is WST's earnings growth rate?

WST compound annual EPS growth rates (CAGR): 1-Year: +1.6%, 3-Year: -4.2%, 5-Year: +8.3%, 10-Year: +18.0%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2025.

What are WST's profit margins?

West Pharmaceutical Services, Inc. net profit margin is +16.1%, operating margin is +20.1%, and gross margin is +35.9%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +16.9%.

Is WST growing earnings?

WST earnings growth is slowing. Current YoY EPS growth of +1.6% trails the 5-year CAGR of +8.3%. TTM net income is $543M.

What was WST's best earnings year?

West Pharmaceutical Services, Inc.'s highest annual net income on record is $662M, achieved in fiscal year 2021. Earnings history on this page spans 1989 to 2025 and includes all annual and quarterly figures.

What were WST's earnings last quarter?

WST's most recent reported quarter was Q1 2026. Net income was $139M with diluted EPS of $1.92. For a full breakdown of all quarters, see the quarterly earnings table on this page.

WST Earnings Over Time (1989–2025)

Net income & EPS — annual and quarterly view